BankChampaign National Association Takes Position in Guardant Health, Inc. $GH

BankChampaign National Association acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 8,756 shares of the company’s stock, valued at approximately $809,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GH. AQR Capital Management LLC increased its position in Guardant Health by 56.5% in the 1st quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock valued at $3,012,000 after acquiring an additional 25,831 shares during the period. Empowered Funds LLC acquired a new position in Guardant Health during the 1st quarter worth $274,000. Sei Investments Co. boosted its position in Guardant Health by 15.8% during the 2nd quarter. Sei Investments Co. now owns 77,308 shares of the company’s stock worth $4,023,000 after acquiring an additional 10,538 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Guardant Health by 9.4% in the second quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company’s stock worth $32,922,000 after purchasing an additional 54,284 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Guardant Health by 56.4% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company’s stock worth $5,800,000 after purchasing an additional 40,209 shares in the last quarter. 92.60% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Guardant Health news, CEO Helmy Eltoukhy sold 100,000 shares of Guardant Health stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the transaction, the chief executive officer directly owned 2,012,919 shares in the company, valued at approximately $254,231,669.70. The trade was a 4.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Musa Tariq sold 1,951 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $131.16, for a total transaction of $255,893.16. Following the sale, the director directly owned 11,048 shares in the company, valued at approximately $1,449,055.68. This trade represents a 15.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 708,565 shares of company stock worth $90,556,597 in the last quarter. Corporate insiders own 5.60% of the company’s stock.

Guardant Health Price Performance

Shares of GH opened at $152.35 on Friday. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $174.08. The company has a 50-day moving average of $142.58 and a two-hundred day moving average of $113.03. The stock has a market cap of $20.20 billion, a price-to-earnings ratio of -44.94 and a beta of 1.59.

Analysts Set New Price Targets

GH has been the topic of a number of recent analyst reports. Guggenheim lifted their price objective on shares of Guardant Health from $160.00 to $190.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. The Goldman Sachs Group began coverage on shares of Guardant Health in a research note on Friday, June 5th. They set a “buy” rating and a $165.00 target price on the stock. Sanford C. Bernstein boosted their price target on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, July 2nd. Barclays upped their price target on shares of Guardant Health from $120.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Finally, Canaccord Genuity Group increased their price objective on shares of Guardant Health from $135.00 to $205.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $164.59.

Trending Headlines about Guardant Health

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Revenue and testing growth exceeded expectations. Second-quarter revenue rose 44% year over year to $335.0 million, surpassing the $314.2 million consensus estimate. Oncology revenue increased 38% to $219.1 million, while oncology testing volume jumped 63% to approximately 104,000 tests. Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: The adjusted loss narrowed substantially. Guardant Health reported a second-quarter loss of $0.42 per share, better than the $0.76-per-share analyst estimate and improved from a $0.44 loss in the year-ago quarter. The earnings beat signals better operating leverage despite the company remaining unprofitable. Guardant Health Q2 Adjusted Loss Narrows, Revenue Rises
• Positive Sentiment: Guardant raised its fiscal 2026 revenue guidance to approximately $1.3 billion-$1.4 billion, compared with analyst expectations near $1.3 billion. The outlook increase reinforces confidence in demand for its precision-oncology testing products and was a key catalyst for the stock’s gain. Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Neutral Sentiment: Management is scheduled to participate in investor conferences in August and September, providing potential opportunities to discuss growth, guidance and the path toward profitability. Guardant Health to Participate in Upcoming Investor Conferences

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.